Posts With Tag multiple sclerosis treatment

Tiziana Life Sciences LTD's Form 6-K reveals progress in their ISPPEA program for treating non-active secondary progressive MS, with promising patient outcomes.

Discover Sanofi's latest Form 6-K, detailing FDA designations and promising study results for Tolebrutinib and Duvakitug, crucial for investors and stakeholders.